A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

INTRODUCTION: Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to de...

詳細記述

保存先:
書誌詳細
主要な著者: Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979046/
https://ncbi.nlm.nih.gov/pubmed/24252402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3577
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料